معرفی
Matthew Gumbleton is a Clinical Assistant Professor in the Department of Internal Medicine at the University of Utah School of Medicine. He is affiliated with the Huntsman Cancer Institute, where he specializes in lung cancer, thoracic oncology, and medical oncology. His clinical expertise includes invasive mucinous adenocarcinoma of the lung and patient-centered care, as evidenced by a 5.0/5 patient rating from 54 reviews.
Education:
- PhD in Microbiology & Immunology, SUNY Upstate Medical University
- MD, SUNY Upstate Medical University
- B.S. in Microbiology & Immunology, Kalamazoo College
- Internship & Residency in Internal Medicine, University of Utah School of Medicine
- Postdoctoral Fellowship in Medical Oncology and Lung Cancer, Huntsman Cancer Institute
Gumbleton's research focuses on SHIP1 (SH2 domain-containing inositol-5'-phosphatase 1) and its role in natural killer (NK) cell biology, hematopoietic stem cell transplantation, and antitumor immunity. His work explores how SHIP1 inhibition enhances NK cell activation and improves outcomes in cancer therapy, including patent filings for SHIP1-targeted treatments. His publications span immunology, oncology, and molecular signaling pathways.
Recent studies highlight his contributions to phase I trials combining apatinib with pembrolizumab for advanced malignancies (2023), the interplay of SHIP1 inhibition with NK and T cell function (2017), and SHIP1's regulatory role in hematopoietic stem cell homeostasis during aging (2015). His work bridges clinical oncology with fundamental immunological mechanisms.
Labs & Teams: Gumbleton is associated with the Huntsman Cancer Institute, where he conducts translational research linking immune signaling to cancer treatment strategies.
